Check 35,000+ stocks against 26 valuation models and 37 quality factors

Puriblood Medical Co., Ltd. (6847) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Puriblood Medical Co., Ltd. TWD 60.48, price TWD 72.30, upside -16.4%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · TW · ISIN TW0006847007

PM Thin data Sep 24, 2026

Puriblood Medical Co., Ltd.

6847 · TWO

Weak valuationQuality is weak on top of the rich price.

!Fair value 60.48 TWD · Overvalued (−16%)

!Quality 46/100

!Weak Growth (revenue 5y +16.3 %/yr)

!Loss-making · -47.4% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (3/10)

!Narrow moat 6/100

!Evidence only low, so the estimate is less certain

!Weak on valuation: 12 out of 100

26 models, one by oneBear 40.11 TWD to bull 75.76 TWD Growth analysisrevenue history, year by year Quality 46/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Puriblood Medical Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range 47.85 TWD – 88.70 TWD · fair‑value band 40.11 TWD – 75.76 TWD · the 72.30 TWD price screens above the 60.48 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Follow Puriblood Medical Co. in your weekly email

Every Wednesday you see whether Puriblood Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd.

Stock analysis

Puriblood Medical Co., Ltd. (6847) currently trades at 72.30 TWD, while our model-based Fair Value estimate is 60.48 TWD, implying the stock looks roughly 19.5% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 40.11 TWD (bear) to 75.76 TWD (bull), the price of 72.30 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Puriblood Medical Co., Ltd. reported revenue of 82.3M TWD in FY2025 versus 54.6M TWD in FY2021, a compound +10.8%/yr. Reported net income was −39.0M TWD in FY2025.

Key figures

Market cap 1.0B TWD (≈ $32.4M) · P/S ratio 12.6 · EPS (TTM) −2.74 TWD · Net margin −47.4% · Return on equity −24.7% · Return on assets (EBIT) −9.0% · Operating margin −54.4% · Revenue (TTM) 82.3M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −16%, 6847 screens richer than that median.

Fair Value models

Bear 40.11 TWD Fair Value 60.48 TWD Bull 75.76 TWD

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) 4.93 TWD 6.60 TWD 9.85 TWD 54

All 1 models by family

Asset-Based

NCAV (Graham) 4.93 TWD 6.60 TWD 9.85 TWD 54

Open the full fair value analysis →

Notify me when 6847 reaches fair value

Put 6847 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 47 · Market factors (momentum, volatility) 45

Profitability 8

Margins and returns on capital today

Quality Growth 22

Are margins and returns improving?

Cashflow 5

Earnings quality: real cash, not paper profit

Fin. Strength 91

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 37

Price trend over the last 3–12 months (market factor)

52W Momentum 53

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−25.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−15.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.3%

Start year 2020 (pandemic)

Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+72.8%

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−8.5% (2020) → −40.6% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

6847 screens 20% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Puriblood Medical Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 3/9 measures

Overall it trails its industry peers.

Valuation

Quality Score 47 · Below median

Fair Value upside −16% · Above median

Profitability

Return on assets −8% · Bottom 25%

Net margin (TTM) −47% · Bottom 25%

Operating margin (TTM) −54% · Bottom 25%

Growth and dividend

Revenue growth −45% · Bottom 25%

Balance sheet

Debt / equity 0.13× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.23× · Cheapest 25%

P/S (TTM) 0.39× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)12 · sector 0

FUTURE (revenue growth)0 · sector 25

PAST (return on equity)0 · sector 8

HEALTH (low debt)93 · sector 95

DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$665.30	$682.58	+3%
Danaher Corporation DHR	$221.09	$207.76	−6%
WuXi AppTec Co 2359	HK$207.60	HK$228.36	+10%
Lonza Group LONN	CHF 570.00	CHF 151.69	−73%
IDEXX Laboratories, Inc IDXX	$522.02	$495.84	−5%
Agilent Technologies, Inc A	$165.32	$63.90	−61%
Waters Corporation WAT	$425.74	$106.31	−75%
IQVIA Holdings IQV	$270.09	$295.80	+10%
Illumina, Inc ILMN	$255.38	$280.92	+10%
Mettler-Toledo International Inc MTD	$1,491	$635.75	−57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Puriblood Medical Co., Ltd. · Fair Value
60.48 TWD −20%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/6847" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Puriblood Medical Co., Ltd. · Fair Value</span><br><b style="font-size:20px">60.48 TWD</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−20%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Puriblood Medical Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6847

Frequently asked questions

Is Puriblood Medical Co., Ltd. (6847) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of 60.48 TWD versus a price of 72.30 TWD, about −16% upside (overvalued).

What is the fair value of 6847?

Our model-based fair value for Puriblood Medical Co., Ltd. is 60.48 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 72.30 TWD.

What is the quality score of 6847?

Puriblood Medical Co., Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Puriblood Medical Co., Ltd. (6847)?

Our model-based price target is the fair value of 60.48 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 40.11 TWD, optimistic scenario 75.76 TWD. It is a calculation from audited fundamentals, not an analyst target.

What is the Puriblood Medical Co., Ltd. stock forecast for 2026?

Our models put fair value at 60.48 TWD, about −16% upside versus a price of 72.30 TWD (overvalued). Cautious scenario 40.11 TWD, optimistic scenario 75.76 TWD. The calculation is refreshed regularly with new filings.

What is the revenue of Puriblood Medical Co., Ltd. (6847)?

Puriblood Medical Co., Ltd. reported trailing-twelve-month revenue of about 82.3M TWD (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of Puriblood Medical Co., Ltd. (6847)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Puriblood Medical Co., Ltd. it is 60.48 TWD per share (as of Sep 24, 2026), against a price of 72.30 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Puriblood Medical Co., Ltd. stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 6847 trades above its calculated fair value: price 72.30 TWD, fair value 60.48 TWD, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 6847?

No. The price is what the market pays today (72.30 TWD); the fair value is what the company's own numbers justify (60.48 TWD). For Puriblood Medical Co., Ltd. the two are 11.82 TWD per share apart. That gap is exactly why we show both numbers side by side.

How much is Puriblood Medical Co., Ltd. worth?

The market values Puriblood Medical Co., Ltd. at about 1.0B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 72.30 TWD; our models calculate a fair value of 60.48 TWD per share.

What do the bullish and bearish scenarios say about 6847?

Our models span a range for Puriblood Medical Co., Ltd.: cautious scenario 40.11 TWD, base 60.48 TWD, optimistic 75.76 TWD per share (as of Sep 24, 2026, price 72.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Puriblood Medical Co., Ltd. (6847)?

Balance-sheet figures for Puriblood Medical Co., Ltd. (as of Sep 24, 2026): return on equity −24.7%, debt of 0.13 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.

Which stocks are comparable to Puriblood Medical Co., Ltd.?

From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Puriblood Medical Co., Ltd. stock attractive at the current price?

The data as of Sep 24, 2026: price 72.30 TWD, calculated fair value 60.48 TWD (−16%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 6847 calculated?

We run Puriblood Medical Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 60.48 TWD, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.0 % above its aggregate fair value. Puriblood Medical Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Puriblood Medical Co., Ltd. (6847)?

The closing price on Sep 24, 2026 was 72.30 TWD. Our model-based fair value is 60.48 TWD, about −16% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Puriblood Medical Co., Ltd. right now?

Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (40.11 TWD to 75.76 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Puriblood Medical Co., Ltd.

How large is the market capitalisation of Puriblood Medical Co., Ltd. (6847)?

The market capitalisation of Puriblood Medical Co., Ltd. is 1.0B TWD (≈ $32.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Puriblood Medical Co., Ltd. (6847)?

The price-to-sales ratio of Puriblood Medical Co., Ltd. is 12.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Puriblood Medical Co., Ltd. (6847)?

Earnings per share at Puriblood Medical Co., Ltd. are −2.74 TWD. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Puriblood Medical Co., Ltd. (6847)?

The net margin of Puriblood Medical Co., Ltd. is −47.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Puriblood Medical Co., Ltd. (6847)?

The return on equity (ROE) of Puriblood Medical Co., Ltd. is −24.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Puriblood Medical Co., Ltd. (6847)?

On an EBIT basis the return on assets of Puriblood Medical Co., Ltd. is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Puriblood Medical Co., Ltd. (6847)?

The operating margin of Puriblood Medical Co., Ltd. is −54.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Puriblood Medical Co., Ltd. (6847)?

Revenue at Puriblood Medical Co., Ltd. is growing −45.4% versus a year earlier (3y avg −15.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Puriblood Medical Co., Ltd. (6847) generate?

The free cash flow of Puriblood Medical Co., Ltd. is −27.9M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Puriblood Medical Co., Ltd. (6847) hold?

Puriblood Medical Co., Ltd. holds more cash than debt, 34.8M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Puriblood Medical Co., Ltd. in the live analysis

One click puts Puriblood Medical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.